Table 4 Univariate and multivariate analysis of DLT events in male and female head and neck cancer patients

Lean body mass (kg)

0.94 (0.88–1.01)

1.15 (0.83–1.59)

Skeletal muscle index (cm²/m²)

0.95 (0.9–1.01)

1.08 (0.81–1.42)

Docetaxel per kilogram lean body mass (mg/kg)^a

 Lower third

1

1

1

 Middle third

1.43 (0.55–3.74)

1.52 (0.57–4.01)

-

 Upper third

2.86 (1.16–7.04)

3.18 (1.25–8.09)

1 (0.05–22)

Cisplatin per kilogram lean body mass (mg/kg)^a

 Lower third

1

1

 Middle third

1.43 (0.55–3.74)

-

 Upper third

2.86 (1.16–7.04)

1 (0.05–22)

Age

0.99 (0.95–1.03)

0.86 (0.72–1.04)

Tumor stage

 cT3-4 vs cT1-2

0.69 (0.33–1.43)

0.4 (0.02–8.07)

 cN2-3 vs cN0-1

2.01 (0.88–4.59)

1 (0.05–19.36)

Tumor subsites

 Oral cavity

1

-

 Oropharynx

1.46 (0.62–3.43)

-

 Hypopharynx/Larynx

2.05 (0.84–5.04)

-

 Others

0.79 (0.09–7.25)

-

Comorbidities

 Chronic liver disease

3.25 (0.89–11.86)

3.98 (1.03–15.46)

-

 Hypertension

0.71 (0.25–2.03)

-

 Diabetes

0.40 (0.09–1.82)

-

Laboratory data

 WBC (× 1000/uL)

0.98 (0.89–1.09)

0.20 (0.02–2.06)

 Hemoglobin (g/dL)

1.03 (0.84–1.25)

1.77 (0.47–6.6)

 Platelet (× 1000/uL)

1.00 (0.99–1.00)

0.99 (0.98–1.02)

 BUN (mg/dL)

0.97 (0.91–1.04)

052 (0.14–1.96)

 Creatinine (mg/dL)

0.52 (0.051–5.2)

-

 eGFR (ml/min/1.73m²)

1.01 (0.99–1.03)

0.99 (0.9–1)

 Sodium (mEq/L)

1.03 (0.92–1.15)

1.32 (0.67–2.60)

 Potassium (mEq/L)

0.95 (0.5–1.8)

-

 Albumin (g/dL)

0.75 (0.32–1.79)

-

 Abnormal GOT^b

2.59 (0.90–7.45)

-

 Abnormal GPT^b

2.30 (0.94–5.63)

 2.61 (1.03–6.64)

-

 Abnormal total bilirubin^b

-

-

Hematoloigcal markers

 Neutrophil to lymphocyte ratio

1.06 (0.9–1.14)

0.74 (0.28–1.96)

 CRP/Albumin

1.05 (0.57–1.93)

1.32 (-)

mGPS

 mGPS 0

1

 mGPS 1

0.54 (0.18–1.6)

-

 mGPS 2

1.69 (0.49–5.77)

-